**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 72702

**Manuscript Type:** CASE REPORT

**Clinical features and genetic variations of severe neonatal hyperbilirubinemia: Five case reports**

Lin F *et al*. Neonates with severe hyperbilirubinemia

Fen Lin, Jian-Xin Xu, Yong-Hao Wu, Yu-Bin Ma, Li-Ye Yang

**Fen Lin, Jian-Xin** **Xu, Yong-Hao Wu,** Precision Medical Center, Chaozhou Central Hospital Affiliated to Southern Medical University, Chaozhou 521021, Guangdong Province, China

**Fen Lin,** Department of Biochemistry, Shantou University Medical College, Shantou 515000, Guangdong Province, China

**Yu-Bin Ma,** Department of Pediatrics, Chaozhou Central Hospital Affiliated to Southern Medical University, Chaozhou 521000, Guangdong Province, China

**Li-Ye Yang,** Precision Medical Lab Center, People’s Hospital of Yangjiang Affiliated to Guangdong Medical University, Yangjiang 529500, Guangdong Province, China

**Author contributions:** Yang LY conceived the study and revised the manuscript; Lin F performed all experiments and wrote the manuscript; Xu JX collected the blood samples and biochemical analyses of the patients; Wu YH collected the clinical data, and Ma YB performed the treatments; All authors read and approved the final manuscript.

**Corresponding author: Li-Ye Yang, MD, Professor,** Precision Medical Lab Center, People’s Hospital of Yangjiang Affiliated to Guangdong Medical University, No. 42 Dongshan Road, Jiangcheng District, Yangjiang 529500, Guangdong Province, China. yangleeyee@sina.com

**Received:** November 1, 2021

**Revised:** April 6, 2022

**Accepted: May 22, 2022**

**Published online:**

**Abstract**

BACKGROUND

Neonatal hyperbilirubinemia is a common problem faced by pediatricians. The role of genetic factors in neonatal jaundice has been gradually recognized. This study aims to identify genetic variants that influence the bilirubin level in five patients using next-generation sequencing (NGS).

CASE SUMMARY

Five neonates with severe hyperbilirubinemia were retrospectively studied. They exhibited bilirubin encephalopathy, hypothyroidism, ABO blood type incompatibility hemolysis, glucose-6-phosphate dehydrogenase (*G6PD*) deficiency and premature birth, respectively. A customized 22-gene panel was designed, and NGS was carried out for these neonates. Eight variations (*G6PD* c.G1388A, *HBA2* c.C369G, *ABCC2* c.C3825G, *UGT1A1* c.G211A, *SPTB* c.A1729G, *EPB41* c.G520A, c.1213-4T>G and c.A1474G) were identified in these five neonates. Genetic mutations of these genes are associated with *G6PD* deficiency, thalassemia, Dubin-Johnson syndrome, Gilbert syndrome, hereditary spherocytosis, and hereditary elliptocytosis. One of the neonates was found to have compound variants of the *EPB41* splice site c.1213-4T>G and c.G520A (p.E174K), but no elliptocyte was seen on his blood smear of 4 years old.

CONCLUSION

Pathological factors of severe neonatal hyperbilirubinemia are complicated. Genetic variants may play an important role in an increased risk of neonatal hyperbilirubinemia, and severe jaundice in neonates may be related to a cumulative effect of genetic variants.

**Key Words:** Neonatal hyperbilirubinemia; Gene variation; Next generation sequencing; Clinical feature; Case report

Lin F, Xu JX, Wu YH, Ma YB, Yang LY. Clinical features and genetic variations of severe neonatal hyperbilirubinemia: Five case reports. *World J Clin Cases* 2022; In press

**Core Tip:** This study has emphasized that for severe hyperbilirubinemia neonates, apart from the predominant glucose-6-phosphate dehydrogenase deficiency and ABO hemolysis, other underlying genetic factors such as thalassemia or red blood cell membrane disorders should be considered, and genetic detection may be taken into consideration for early diagnosis of severe hyperbilirubinemia in neonates.

**INTRODUCTION**

Hyperbilirubinemia is one of the most prevalent clinical symptoms in neonates. The main feature of neonatal hyperbilirubinemia is increased bilirubin production, which leads to abnormal bilirubin deposition in the mucosa, skin and organs. Severe hyperbilirubinemia may cause bilirubin encephalopathy and kernicterus and can result in hearing loss, cerebral palsy and disorders of mental development[1]. The importance of genetic contributions in neonatal jaundice has been recognized in recent years[2-5]. We previously demonstrated that the genetic polymorphisms of uridine diphosphate glucuronosyltransferase 1A1 (*UGT1A1*), solute carrier organic anion transporter family member 1B1 (*SLCO1B1*), *SLCO1B3* and glucose-6-phosphate dehydrogenase (*G6PD*) contributed to an increased risk of neonatal hyperbilirubinemia, which reflected the complexity of pathological jaundice[6,7].

Next-generation sequencing (NGS) is an effective tool for genomic screening and is widely used for the molecular diagnosis of pediatric diseases. Here, we present five neonates with severe hyperbilirubinemia and use NGS technology to explore the genetic variants.

**CASE PRESENTATION**

***Chief complaints***

**Case 1:** A 5-d-old male neonate was referred to our hospital with chief complaints of vomiting and jaundiced skin for 4 d.

**Case 2:** A 6-d-old male neonate was referred to our hospital with chief complaint of jaundiced skin for 3 d.

**Case 3:** A 4-d-old male neonate with chief complaint of jaundiced skin for 1 d.

**Case 4:** A 28-d old female neonate was admitted to our hospital with chief complaints of yellow skin and weight stagnation for 25 d.

**Case 5:** A 7-d-old male neonate was admitted to our hospital with chief complaint of yellow skin for 5 d.

***History of present illness***

**Case 1:** The neonate was delivered vaginally with a birth weight of 3.15 kg and received formula feeding. His mother was para 2 and gravida 2. He appeared icteric and vomited milk on day 2 after birth. The yellowing of his skin increased gradually. He was admitted on day 5.

**Case 2:** The patient was a cesarean born neonate with a birth weight of 3.10 kg. He was breastfed. He had a mother of gravida 2 and para 2. He was found with jaundiced skin for 3 d.

**Case 3:** The neonate was cesarean born to a mother of gravida 1, para 1, and the blood type of his mother was O. His birth weight was 3.30 kg. He was found with yellow skin for 1 d.

**Case 4:** The neonate was born to a mother of gravida 1 and para 1 by cesarean section, she was breastfed, and did not receive neonatal screening, she showed yellow skin at 4 days of birth, her yellow skin continued to her admission in our hospital (age: 28 d), her body weight did not increased after her birth (birth weight 3.25 kg).

**Case 5:** The neonate was delivered vaginally because of premature rupture of the membrane, his birth weight was 2.65 kg. His mother was gravida 1 and para 1, he was admitted to our hospital due to yellow skin for 5 d.

***History of past illness***

The neonates had no other previous medical history.

***Personal and family history***

The neonates had no significant family history.

***Physical examination***

**Case 1:** The neonate was found with severe yellow skin and mucous, and abdominal distention were observed during physical examination.

**Case 2:** Severe yellow skin and mucous were observed during physical examination. His muscle tension and limb activities appeared normal, and he did not show fever or convulsion.

**Case 3:** Mild yellow skin and yellow sclera.

**Case 4:** Severe yellow skin and sclera.

**Case 5:** Severe yellow skin and mild yellow mucous were observed during physical examination.

***Laboratory examinations***

**Case 1:** A blood test was performed. His hemoglobin (Hb) was 147g/L, and his total bilirubin (TBIL) increased significantly (719.50 μmol/L, normal upper limit: 20.1 μmol/L), and his *G6PD* activity was 0.4 (normal range: 1.1-2.5) (Table 1).

**Case 2:** The TBIL level was 360 μmol/L on admission. Phototherapy was carried out three times, and the TBIL level decreased to 260 μmol/L on day 9 after birth. He was released and resumed breastfeeding. However, his skin yellowing gradually increased postdischarge, so he was readmitted on day 12 of life for treatment. He had a TBIL level of 527.87 μmol/L, and a complete blood count revealed a Hb level of 105 g/L. Moreover, the *G6PD* activity was 0.5.

**Case 3:** His blood test showed Hb levels of 143 g/L, and he was blood group B and Rh D-positive. Free antibody tests and antibody release tests were positive. He was diagnosed with ABO incompatibility with a TBIL level of 429.6 μmol/L on day 4 after birth, and he had a heterozygous *EPB41* c.A1474G (p.T492A) mutation (Table 2).

**Case 4:** Serological examination showed increased TBIL (538.7 μmol/L) and thyrotropin levels (150 mIu/L, reference 0.35-5.5) with low free triiodothyronine (0.1 pmol/L, reference 3.5-6.5) and free thyroxine (0.60 pmol/L, reference 11.5-22.7) levels. Two heterozygous mutations, *SPTB* c.A1729G (p.I577V) and *ABCC2* c.3825C>G (p.Tyr1275X), were confirmed in this neonate.

**Case 5:** The TBIL level was 538.7 μmol/L on day 7 after birth.

***Imaging examinations***

**Case 1:** A barium meal examination showed congenital hypertrophic pyloric stenosis (CHPS).

**Case 2:** Head magnetic resonance imaging showed signal changes on T1WI and T2WI.

**FINAL DIAGNOSIS**

**Case 1:** The neonate was diagnosed with neonatal hyperbilirubinemia and CHPS.

**Case 2:** He was diagnosed as *G6PD* deficiency, neonatal hyperbilirubinemia, moderate anemia and bilirubin encephalopathy.

**Case 3:** The neonate was diagnosed as ABOblood type incompatibility hemolytic disease of newborn.

**Case 4:** The neonate was diagnosed as hypothyroidism and hyperbilirubinemia.

**Case 5:** The neonate was diagnosed as neonatal hyperbilirubinemia. This neonate was heterozygous for the *UGT1A1* c.G211A (p.G71R) mutation.

**TREATMENT**

**Case 1:** He received phototherapy for three days (the indication of phototherapy according to the expert consensus for diagnosis and treatment of neonatal hyperbilirubinemia in *Chinese Journal of Pediatrics* 2014)[8]. Subsequently, he was transferred to the Women and Children's Hospital of Guangdong Province and underwent a surgical operation for CHPS. Two weeks later, he recovered and was discharged. Genetic analysis revealed that he carried the *G6PD* c.G1388A mutation, and he was also a compound heterozygote for the c.1213-4T>G and c.G520A (p.E174K) mutations of the *EPB41* gene (Table 2).

**Case 2:** He received phototherapy, alkalization of urine, and vitamin K1 supplementation and was subjected to red blood cell (RBC) transfusion (Hb dropping to 95 g/L). The *G6PD* c.G1388A and *HBA2* c.C369G (Hb Westmead) mutations were identified in this neonate (Table 2).

**Case 3:** The neonate received routine phototherapy.

**Case 4:** Levothyroxine therapy was initiated (48 μg daily) to adjust the inadequate secretion of thyroxine.

**Case 5:** The neonate received routine phototherapy.

**OUTCOME AND FOLLOW-UP**

The five children were followed up, and their intelligence and development were normal.

**DISCUSSION**

Pathologic jaundice refers to an abnormal increase in serum bilirubin levels, and a pathological investigation to determine hyperbilirubinemia is important in clinical practice to prevent the adverse reactions of severe jaundice. Routine laboratory test results may fail to explain jaundice severity, and we hypothesized that genetic factors might contribute to the development of severe hyperbilirubinemia. In the present study, we analyzed five neonates who had severe hyperbilirubinemia due to *G6PD* deficiency, ABO blood type incompatibility hemolysis, premature delivery and hypothyroidism, which were the most common etiological factors of pathological jaundice in the neonatal period. We also confirmed nine gene variants through NGS.

Based on our results, all five neonates carried at least one genetic variant, and the associated disorders included *G6PD* deficiency, α-thalassemia, hereditary elliptocytosis, hereditary spherocytosis, Dubin-Johnson syndromes and Gilbert’s syndrome[9-12]. A previous study reported a case of neonate that had both *G6PD* deficiency and a heterozygous variant of the *UGT1A1* promoter (TA)6/(TA)7 who developed severe hyperbilirubinemia and bilirubin encephalopathy[13]. Butorac Ahel *et al*[14] reported a case of infant with unusually severe hyperbilirubinemia due to the coexistence of hereditary spherocytosis and homozygosity for *UGT1A1* (TA)7. Our report of 5 patients also confirmed that genetic variations of susceptible genes (Figure 1) contributed to the development of neonatal hyperbilirubinemia and severe jaundice in neonates might be related to a cumulative effect of genetic variants.

Notably, to our knowledge, hereditary elliptocytosis (HE) is a congenital red cell membrane disorder characterized by elliptically shaped cells, and the *EPB41* genetic variant is one of the most identified defects. Case 1 was found to have variants for both the *EPB41* splice site c.1213-4T>G and c.G520A (p.E174K). In silico predictions concluded that the above two variants were likely to be damaging or possibly damaging. Generally, HE patients with a single heterozygous mutation are often considered to be asymptomatic, but homozygous mutations or compound heterozygous mutations exhibit moderate to severe hemolysis[15]. However, no splenomegaly, reticulocyte level abnormality or hemolytic anemia was observed in this patient after follow-up for 4 years (data not shown). We propose that the two genetic variations may aggravate the jaundice levels in this case. A previous study noted that spherical-shaped red cells were rarely observed in neonates, which was likely due to the immature RBC membranes of neonates[16]. This neonate did not receive a blood smear when he was in the hospital. He received a routine examination at 4 years old, and no elliptocyte was seen on his blood smear. The absence of elliptical-shaped erythrocyte in this patient reflects the high heterogeneity of hereditary elliptocytosis. Moreover, although case 4 was clinically diagnosed with hypothyroidism, no genetic variation associated with hypothyroidism was found (data not shown).

**CONCLUSION**

In conclusion, our study emphasized that for neonates with severe hyperbilirubinemia, apart from the predominant *G6PD* deficiency and ABO blood type incompatibility hemolysis, other underlying genetic factors, such as thalassemia or RBC membrane disorders, should be considered. Furthermore, genetic detection should be considered for the early diagnosis of severe hyperbilirubinemia in neonates.

**REFERENCES**

1 **Olusanya BO**, Kaplan M, Hansen TWR. Neonatal hyperbilirubinaemia: a global perspective. *Lancet Child Adolesc Health* 2018; **2**: 610-620 [PMID: 30119720 DOI: 10.1016/S2352-4642(18)30139-1]

2 **He CH**, Qu Y. [Research advances in neonatal hyperbilirubinemia and gene polymorphisms]. *Zhongguo Dang Dai Er Ke Za Zhi* 2020; **22**: 280-284 [PMID: 32204767 DOI: 10.7499/j.issn.1008-8830.2020.03.018]

3 **Huang MJ**, Lin YC, Liu K, Chang PF, Huang CS. Effects of variation status and enzyme activity for UDP-glucuronosyltransferase 1A1 gene on neonatal hyperbilirubinemia. *Pediatr Neonatol* 2020; **61**: 506-512 [PMID: 32571672 DOI: 10.1016/j.pedneo.2020.05.009]

4 **Zhou JF**, Luo JY, Zhu WB, Yang CY, Zeng YL, Qiu XL. Association between genetic polymorphism of heme oxygenase 1 promoter and neonatal hyperbilirubinemia: a meta-analysis. *J Matern Fetal Neonatal Med* 2021; **34**: 12-23 [PMID: 30700176 DOI: 10.1080/14767058.2019.1570115]

5 **Li Z**, Song L, Hao L. The role of UGT1A1 (c.-3279 T > G) gene polymorphisms in neonatal hyperbilirubinemia susceptibility. *BMC Med Genet* 2020; **21**: 218 [PMID: 33158427 DOI: 10.1186/s12881-020-01155-2]

6 **Yang H**, Wang Q, Zheng L, Lin M, Zheng XB, Lin F, Yang LY. Multiple Genetic Modifiers of Bilirubin Metabolism Involvement in Significant Neonatal Hyperbilirubinemia in Patients of Chinese Descent. *PLoS One* 2015; **10**: e0132034 [PMID: 26146841 DOI: 10.1371/journal.pone.0132034]

7 **Yang H**, Wang Q, Zheng L, Zheng XB, Lin M, Zhan XF, Yang LY. Clinical Significance of UGT1A1 Genetic Analysis in Chinese Neonates with Severe Hyperbilirubinemia. *Pediatr Neonatol* 2016; **57**: 310-317 [PMID: 26727668 DOI: 10.1016/j.pedneo.2015.08.008]

8 **Editorial Board of Chinese Journal of Pediatrics**; Subspecialty Group of Neonatology, The Society of Pediatrics, Chinese Medical Association. [Experts consensus on principles for diagnosis and treatment of neonatal jaundice]. *Zhonghua Er Ke Za Zhi* 2010; **48**: 685-686 [PMID: 21092529]

9 **Boo NY**, Sin S, Chee SC, Mohamed M, Ahluwalia AK, Ling MM, Ong HK. Genetic Factors and Delayed TSB Monitoring and Treatment as Risk Factors Associated with Severe Hyperbilirubinemia in Term Neonates Admitted for Phototherapy. *J Trop Pediatr* 2020; **66**: 569-582 [PMID: 32577754 DOI: 10.1093/tropej/fmaa016]

10 **Kaplan M**, Wong RJ, Stevenson DK. Hemolysis and Glucose-6-Phosphate Dehydrogenase Deficiency-Related Neonatal Hyperbilirubinemia. *Neonatology* 2018; **114**: 223-225 [PMID: 29940590 DOI: 10.1159/000489820]

11 **Li Y**, Wu T, Chen L, Zhu Y. Associations between G6PD, OATP1B1 and BLVRA variants and susceptibility to neonatal hyperbilirubinaemia in a Chinese Han population. *J Paediatr Child Health* 2019; **55**: 1077-1083 [PMID: 30636082 DOI: 10.1111/jpc.14346]

12 **Shwe S**, Boo NY, Ong HK, Chee SC, Maslina M, Ling MMM, Ahluwalia AK. Haemoglobin Constant Spring (HbA2: c.427T>C) and Haemoglobin Adana (HbA2: c.179G>A) in jaundiced Malaysian term neonates with clinically significant hyperbilirubinemia. *Malays J Pathol* 2020; **42**: 253-257 [PMID: 32860378]

13 **Mukthapuram S**, Dewar D, Maisels MJ. Extreme Hyperbilirubinemia and G6PD Deficiency With No Laboratory Evidence of Hemolysis. *Clin Pediatr (Phila)* 2016; **55**: 686-688 [PMID: 26453670 DOI: 10.1177/0009922815610630]

14 **Butorac Ahel I**, Baraba Dekanic K, Palcevski G, Roganovic J. An Infant With Unusually High Unconjugated Hyperbilirubinemia Due to Coexistence of Hereditary Spherocytosis and Gilbert Syndrome. *J Pediatr Hematol Oncol* 2018; **40**: e127-e128 [PMID: 29200157 DOI: 10.1097/MPH.0000000000001025]

15 **Ma S**, Qin J, Wei A, Li X, Qin Y, Liao L, Lin F. Novel compound heterozygous SPTA1 mutations in a patient with hereditary elliptocytosis. *Mol Med Rep* 2018; **17**: 5903-5911 [PMID: 29484404 DOI: 10.3892/mmr.2018.8632]

16 **Liu C**, Eun HS, Nah H, Lee ST, Choi JR, Kim HO. Newborn hereditary elliptocytosis confirmed by familial genetic testing. *Int J Lab Hematol* 2020; **42**: e20-e22 [PMID: 31286676 DOI: 10.1111/ijlh.13079]

**Footnotes**

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 1, 2021

**First decision:** March 23, 2022

**Article in press:**

**Specialty type:** Pediatrics

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Govindarajan KK, India; Huang CS, Taiwan **A-Editor:** Yao QG, China **S-Editor:** Zhang H **L-Editor:** A **P-Editor:** Zhang H

**Figure Legends**

****

**Figure 1 Polymerase chain reaction-****Sanger sequencing results.** The mutation sites are indicated by yellow bands. A: *SPTB*-rs144668591/c.1729A>G heterozygote; B: *UGT1A1*-rs4148323/c.211G>A heterozygote; C: *ABCC2*-rs554976086/c.3825C>G heterozygote; D: *EPB41*-rs188648724/c.1213-4T>G heterozygote; E: *EPB41*-rs201231112/c.520G>A heterozygote; F: *EPB41*-rs778090351/c.1474A>G heterozygote.

**Table 1 Clinical and laboratory characteristics of five neonates with severe hyperbilirubinemia**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Case ID** | **Patient 1** | **Patient 2** | **Patient 3** | **Patient 4** | **Patient 5** |
| Gender | Male | Male | Male | Female | Male |
| Admission time (d) | 5 | 12 | 4 | 28 | 7 |
| Gestational age (wk) | 39 + 5 | 39 | 40 + 3 | 40 | 35 + 4 |
| Birth weight (kg) | 3.15 | 3.1 | 3.3 | 3.25 | 2.65 |
| Mode of delivery | Vaginal | Cesarean | Cesarean | Cesarean | Vaginal |
| Feeding patterns | Formula | Breast | Breast | Formula | Breast |
| Postnatal growth ratardation | + | - | - | + | - |
| Skin and mucous membrane yellowing | + | + | + | + | + |
| Time of jaundice occur after birth (d) | 2 | 3 | 3 | 4 | 2 |
| Maximum TBIL levels (μmol/L)a | 719.5 | 527.87 | 429.6 | 538.7 | 584.4 |
| Age at maximum TBIL (d) | 5 | 12 | 4 | 28 | 7 |
| Phototherapy | + | + | + | + | + |
| RBC transfusion | - | + | - | - | - |
| IVIGb or albumin therapy | + | + | + | - | - |
| Clinical diagnosis | *G6PD* deficiency; Congenital hypertrophic pyloric stenosis; Neonatal hyperbilirubinemia | *G6PD* deficiency; Anemia; Bilirubin encephalopathy | ABO blood type incompatibility hemolytic disease | Congenital hypothyroidism; Neonatal hyperbilirubinemia | Premature delivery; Neonatal hyperbilirubinemia |

aNormal upper limit: 20.1 µmol/L.

bIntravenous immunoglobulin.

+: Present; -: Absent; TBIL: Total bilirubin; RBC: Red blood cell; IVIG: Intravenous immunoglobulin; *G6PD*: Glucose-6-phosphate dehydrogenase.

**Table 2 Causative mutations and potentially pathogenic variants identified in five neonates**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case numbers** | **Gene name** | **rs number** | **cDNA/protein change** | **Mutationtaster prediction** | **PolyPhen2** | **SIFT** | **Genotype** | **Associated disorder** |
| Patient 1 | *EPB41* | rs201231112 | c.G520A/p.E174K | Disease-causing | Probably damaging | Tolerated | Hetero | Elliptocytosis |
|  | *EPB41* | rs188648724 | c.1213-4T>G | Disease-causing |  |  | Hetero | Elliptocytosis |
|  | *G6PD* | rs72554664 | c.G1388A/p.R463H | Disease-causing | Damaging | Deleterious | Hemiz | *G6PD* deficiency |
| Patient 2 | *G6PD* | rs72554664 | c.G1388A/p.R463H | Disease-causing | Damaging | Deleterious | Hemiz | *G6PD* deficiency |
|  | *HBA2* | rs41479347 | c.C369G/p.H123Q | Disease-causing | Probably damaging | Deleterious | Hetero | Thalassemia |
| Patient 3 | *EPB41* | rs778090351 | c.A1474G/p.T492A | Disease-causing | Damaging | Deleterious | Hetero | Elliptocytosis |
| Patient 4 | *SPTB* | rs144668591 | c.A1729G/p.I577V | Disease-causing | Probably damaging | Deleterious | Hetero | Elliptocytosis |
|  | *ABCC2* | rs554976086 | c.C3825G/p.Tyr1275X | Disease-causing | Probably damaging | Deleterious | Hetero | Dubin-Johnson syndrome |
| Patient 5 | *UGT1A1* | rs4148323 | c.G211A/p.G71R | Polymorphism | Probably damaging | Deleterious | Hetero | Gilbert's syndrome |

Hetero: Heterozygote; Hemiz: Hemizygote; *EPB41*: Protein 4.1; *G6PD*: Glucose-6-phosphate dehydrogenase; *HBA2*: Hemoglobin alpha 2; *SPTB*: Spectrin beta; *ABCC2*: Adenosine triphosphate-binding cassette subfamily C member 2; *UGT1A1*: Uridine diphosphate glucuronosyltransferase 1A1.